# A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01233232** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 109 (actual)

## Conditions studied

- Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD)
- Laymen Terminology Chronic Bronchitis and Emphysema

## Interventions

- **DRUG:** Placebo
- **DRUG:** AZD5069 50mg
- **DRUG:** AZD5069 80mg

## Key facts

- **NCT ID:** NCT01233232
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2015-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233232, "A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01233232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*